studies

la/mBC - HR-positive - 1st line (L1), cyclin inhibitor vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsMONALEESA-2, 2016 0.76 [0.63; 0.92] PENELOPE-B, 2021 0.87 [0.61; 1.24] 0.78[0.66; 0.93]MONALEESA-2, 2016, PENELOPE-B, 202120%1,918lownot evaluable iDFSdetailed resultsPENELOPE-B, 2021 0.93 [0.74; 1.17] 0.93[0.74; 1.17]PENELOPE-B, 202110%1,250NAnot evaluable progression or deaths (PFS)detailed resultsMONALEESA-2, 2016 0.56 [0.43; 0.72] MONARCH 3, 2017 0.54 [0.41; 0.72] 0.55[0.46; 0.67]MONALEESA-2, 2016, MONARCH 3, 201720%1,161lownot evaluable CBRdetailed resultsMONALEESA-2, 2016 1.46 [1.02; 2.10] MONARCH 3, 2017 1.42 [0.92; 2.17] 1.44[1.10; 1.90]MONALEESA-2, 2016, MONARCH 3, 201720%1,161lownot evaluable objective responses (ORR)detailed resultsMONALEESA-2, 2016 1.81 [1.31; 2.50] MONARCH 3, 2017 1.76 [1.20; 2.59] 1.79[1.39; 2.29]MONALEESA-2, 2016, MONARCH 3, 201720%1,161lownot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-10 05:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 800,716,1404,967,1443,1406,1338,1337,1369,1375,1249,1407,1376,1411,1379,1403,1381,1380

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons